Bcl-2与NF-κB/p65在弥漫性大B细胞淋巴瘤中的表达及意义  

Expression and clinical significance of Bcl-2 and NF-кB/p65 in diffuse large B-cell lymphoma

作　　者：黄忠连[1] 顾康生[1] 孟刚[1] 

机构地区：[1]安徽医科大学第一附属医院,安徽合肥230022

出　　处：《山东医药》2007年第4期3-4,共2页Shandong Medical Journal

基　　金：安徽省教育厅自然科学研究项目(2003KJ188)

摘　　要：目的探讨Bcl-2与NF-κB/p65蛋白在弥漫性大B细胞淋巴瘤(DLBCL)中的表达及意义。方法采用免疫组化方法检测DLBCL患者Bcl-2和NF-κB/p65蛋白的表达,分析二者与DLBCL临床特征、疗效及预后的关系。结果Bcl-2和NF-κB/p65蛋白在DLBCL中的表达率为51.5%和38.7%,二者表达有相关性;Bcl-2与NF-κB/p65蛋白在DLBCL中的表达与临床分期、疗效及预后有关。结论Bcl-2、NF-κB/p65蛋白检测可作为DLBCL患者不良临床特征及预后较差的指标,并有助于指导个体化药物治疗。[Objective] To investigate the expression and clinical significance of Bcl-2 and NF-κB/p65 in diffuse large B-cell lymphoma. [Methods] Immunohistochemical staining was used to detect the expression of Bcl-2 and NF-κB/p65 in the DLBCL patients. Relation between Bcl-2, NF-κB/p65 and clinical staging, effect and prognosis of DLBCL eases were analyzed. [Results] The expression rates of Bcl-2 and NF-κB/p65 proteins in DLBCL were 51.5% and 38. 7%. There was significant correlation hetween them, The expression rate of Bcl-2 and NF-κB/p65 proteins in DLBCL have relation with clinical staging, effect and prognosis. [Conclusion] Bcl-2 and NF-κB/p65 proteins can be used asmarkers to prognoseeaeoethic clinical feature and poor prognosis in DLB- CL cases and is helpful in guiding personalized medicine.

关 键 词：BCL-2 NF—κB 淋巴瘤 弥漫型 B细胞 预后 

分 类 号：R733.4[医药卫生—肿瘤]